Regeneron – Page 2

Sanofi, Regeneron’s IL-33 Drug Fails One of Two COPD Studies, Casting Doubt on FDA Approval Timeline

5 months ago talkbio0Tagged AERIFY-1, AERIFY-2, Approved, Clinical Trials, COPD, IL33 protein, human, itepekimab, Regeneron, sanofi, United States Food and Drug Administration

Sanofi; Regeneron; COPD; itepekimab; IL-33; Phase 3 trials; AERIFY-1; AERIFY-2; FDA approval; clinical trial results

Regeneron to Acquire 23andMe Out of Bankruptcy for $256 Million

5 months ago talkbio0Tagged Acquisition, Bankruptcy, data privacy, Genetic testing for cancer risk, Genome, personal genome service, Purchased Services, Clinical and Biomedical, Research, Regeneron, total health

Regeneron; 23andMe; acquisition; bankruptcy; genetic testing; genome; personal genome service; total health; research services; data privacy

Regeneron crumples under the weight of missed Eylea expectations

6 months ago talkbio0Tagged decline, earnings, Eylea, Regeneron, Sales - occupational activity, United States Food and Drug Administration

Regeneron, United States Food and Drug Administration, earnings, Eylea, decline, Sales – occupational activity

Regeneron Secures EU Approval for Bispecific Antibody Lynozyfic, Positioning for Competition Against J&J and Pfizer

6 months ago talkbio0Tagged Antibodies, Bispecific, Approved, EU, J&J, Lynozyfic, Multiple Myeloma, Neoplasms, Pfizer, Regeneron

Regeneron, Lynozyfic, Bispecific Antibody, Multiple Myeloma, EU Approval, J&J, Pfizer, Oncology

Regeneron turns to CDMO Fujifilm to boost US manufacturing capacity

6 months ago talkbio0Tagged Biological Factors, Boost, Capacity, CDMO, Fujifilm, Manufacture, Regeneron, United States

Regeneron, Manufacture, Fujifilm, CDMO, Biological Factors, Capacity, United States, Boost

FDA rejection of extended dosing interval is another piece of bad news for Regenerons Eylea HD

6 months ago talkbio0Tagged Age related macular degeneration, Diabetic Retinopathy, dosing, Extension, Eylea HD, Interval, Regeneron, Rejection, United States Food and Drug Administration

United States Food and Drug Administration, Interval, Regeneron, dosing, Extension, Eylea HD, rejection, Age related macular degeneration, Diabetic Retinopathy

A closer look at pharmas top patent losses in 2025

7 months ago talkbio0Tagged 2023, 2025, Bayer, competition, Expiration, function, Impact food supplement, Indication of (contextual qualifier), Legal patent, Market, Patent Cliff, Regeneron, Sales - occupational activity

Legal patent, Expiration, function, Market, Indication of (contextual qualifier), competition, Impact food supplement, Sales – occupational activity, Bayer, 2025, patent cliff, Regeneron, 2023

Federal Circuit ruling allows Amgen’s Eylea biosimilar to stay on the market

8 months ago talkbio0Tagged amgen, Amgen 's, court, Eylea, Eylea biosimilar, Federal Circuit, Market, Pavblu, Regeneron

Market, Amgen ‘s, Pavblu, Amgen, Eylea biosimilar, Regeneron, Federal Circuit, court, Eylea

Truveta Genome Project: A Historic 10M Genome Sequencing Initiative Backed by Regeneron, Illumina, and Leading Health Systems

10 months ago talkbio0Tagged Drug Discovery, genetic sequencing, genome sequencing, Genotype, healthcare analytics, Illumina, phenotypic, Precision Medicine, Regeneron, Truveta

Truveta Genome Project, 10M genome sequencing, Regeneron, Illumina, genetic sequencing, genotypic and phenotypic data, healthcare analytics, drug discovery, personalized medicine.

Regeneron Expands Ophthalmology Portfolio with Acquisition of UK-Based Biotech Oxular

10 months ago talkbio0Tagged Acquisition, biotech, Drug Delivery Systems, Ophthalmology specialty, Oxular, Regeneron, Retinal Diseases, Technology

Regeneron, Oxular, Biotech Acquisition, Ophthalmology, Retinal Disorders, Drug Delivery Technology